Diamedica Therapeutics INC 8-K filings

DiaMedica Therapeutics Inc. announced the results of its 2026 Annual General Meeting, with shareholders re-electing all seven director nominees and approving the company's independent auditor, executive compensation, and an amendment to its incentive plan.

DiaMedica Therapeutics reported Q1 2026 financial results, highlighting progress in its preeclampsia and acute ischemic stroke trials, with cash reserves projected through 2027.

DiaMedica Therapeutics Inc. sold 1,501,000 common shares to a healthcare institution fund, generating $12.2 million in gross proceeds.

DiaMedica Therapeutics announced an update on its DM199 preeclampsia program, revealing the FDA requested an additional non-clinical study, while an ongoing Phase 2 trial shows encouraging interim data.

DiaMedica Therapeutics announced its third quarter 2025 financial results and provided updates on its preeclampsia and acute ischemic stroke clinical programs, including progress in patient enrollment and an extended cash runway.

DiaMedica Therapeutics Inc. has established an At-The-Market equity offering program to sell up to $100 million in common shares through TD Securities (USA) LLC.

DiaMedica Therapeutics announced positive Phase 2 interim data for DM199 in preeclampsia, a $30 million private placement extending its cash runway, and progress in its ReMEDy2 stroke trial.

DiaMedica Therapeutics Inc. announced the appointment of Dr. Julie Krop as Chief Medical Officer, succeeding Dr. Lorianne Masuoka, who resigned for personal reasons.

DiaMedica Therapeutics Inc. announced a $30.1 million private placement of common shares with existing accredited investors to fund its preeclampsia and fetal growth restriction clinical development programs and general corporate purposes.

A biopharmaceutical company announced positive interim Phase 2 study results for its investigational drug DM199 in treating preeclampsia, demonstrating statistically significant reductions in blood pressure and no placental transfer.

DiaMedica Therapeutics successfully held its 2025 Annual General Meeting, electing all director nominees and approving proposals related to auditor appointment and executive compensation.

DiaMedica Therapeutics reported its Q1 2025 financial results, highlighting progress in its DM199 clinical trials for preeclampsia and acute ischemic stroke, and anticipates topline preeclampsia data in the near term.

DiaMedica Therapeutics reports its full year 2024 financial results, provides a business update on its stroke and preeclampsia programs, and announces the appointment of Daniel J. O'Connor to the Board.

Richard Pilnik, a long-standing member of DiaMedica Therapeutics' Board of Directors, will retire and not seek re-election at the company's 2025 Annual General Meeting.

DiaMedica Therapeutics Inc. announced the election of Daniel J. O'Connor to its Board of Directors, effective February 20, 2025.

DiaMedica Therapeutics reported its Q3 2024 financial results and announced key updates to its ReMEDy2 stroke trial, including protocol modifications and a revised timeline for interim results.

DiaMedica Therapeutics reported its second quarter 2024 financial results, provided a business update, and announced a private placement extending its cash runway into Q3 2026.

DiaMedica Therapeutics has announced an $11.8 million private placement to fund its clinical trials, including expansion into preeclampsia.

DiaMedica Therapeutics announces the expansion of its DM199 clinical program into preeclampsia, initiating a Phase 2 trial in Q4 2024 with key results expected in the first half of 2025.

DiaMedica Therapeutics shareholders approved an amendment to the company's 2019 Omnibus Incentive Plan, increasing the number of shares available for issuance by 3,000,000.

DiaMedica Therapeutics has dosed the first patient in the ReMEDy2 stroke trial, expanded its clinical operations team, and reported $46.5 million in cash with a runway to 2026.

DiaMedica Therapeutics reports the resignation of its Senior Vice President of Clinical Development Operations, effective April 18, 2024, with the Vice President of Clinical Operations assuming leadership.

DiaMedica Therapeutics reported its full year 2023 financial results, provided a business update, and announced the commencement of ReMEDy2 clinical site activation.